Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001388034 | SCV001588842 | pathogenic | Familial cancer of breast | 2018-11-16 | criteria provided, single submitter | clinical testing | A gross deletion of the genomic region encompassing the full coding sequence of the CHEK2 gene has been identified. The boundaries of this event are unknown as the deletion extends beyond the assayed region for this gene and therefore may encompass additional genes. While this variant has not been reported in the literature in individuals with CHEK2-related disease, similar loss of the entire CHEK2 coding sequence has been observed in several individuals affected with breast cancer (Invitae). Sub-genic deletions of CHEK2 have been reported in affected patients and are known to be pathogenic (PMID: 16551709, 24763289, 17085682). Therefore, deletions that fully encompass these regions are also expected to be pathogenic. Loss-of-function variants in CHEK2 are known to be pathogenic (PMID: 21876083, 24713400). For these reasons, this variant has been classified as Pathogenic. |